Medical/Pharmaceuticals
China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment
TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world, the Expo showcases the l...
2025-02-05 13:00
2452
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunol...
2025-02-05 12:28
2524
Sequins™ Announces Availability of First Products - Bolsters Team for Commercialization
SAN FRANCISCO, Feb. 4, 2025 /PRNewswire/ -- Sequins, a newly-funded start-up in the next generation sequencing (NGS) ecosystem, announced today the availability of their first commercial products – the Sequins Metagenomics Core Control and Whole Genome Sequencing Core Control Sets, along with an ...
2025-02-05 00:00
2043
GC Labs strengthens global ties and explores new opportunities at Medlab Middle East 2025
YONGIN, South Korea, Feb. 4, 2025 /PRNewswire/ -- GC Labs, a leading clinical
laboratory inSouth Korea, announced the successful completion of the second day
of the Medlab Middle East 2025, which is being held at theDubai World Trade
Centre (DWTC), UAE betweenFebruary 3-6.
2025-02-04 14:56
2528
Lunit Partners with SITC to Launch Exclusive Research Program Featuring Advanced AI Technology for SITC Members
Lunit SCOPE® IO now available to SITC members for AI-powered TME profiling, in a collaborative effort to advance cancer immunotherapy SEOUL, South Korea, Feb. 3, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has en...
2025-02-03 22:00
3288
HoneyNaps' AI-Powered Sleep Diagnostic Software Designated as 73rd and 74th Innovative Medical Device by South Korea's Ministry of Food and Drug Safety
* Simultaneous approval of AI solutions for diagnosing sleep disorders and digital therapeutics for insomnia * Domestic certification secured following U.S. FDA approval * The only company to possess both AI algorithm development and hardware technology BOSTON, Feb. 3, 2025 /PRNewswire/ -- H...
2025-02-03 22:00
2753
China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth
HANGZHOU, China, Feb. 3, 2025 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced it has...
2025-02-03 21:00
4122
Nona Biosciences Announces Strategic Collaboration with Invetx for Next-Generation Animal Health Biotherapeutics Discovery
CAMBRIDGE, Mass., Feb. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), announced today that it has entered into a strategic collaboration with Invetx, Inc. ("Invetx"), aBoston-based animal biotechnology company...
2025-02-03 20:00
2345
Advanced Aesthetic Technologies, Inc. is pleased to announce the approval of Algeness® VL agarose facial injection filler for marketing in China
AAT announces additional significant updates RADNOR, Pa., Jan. 29, 2025 /PRNewswire/ -- Advanced Aesthetic Technologies, Inc. ("AAT") announced today that their partner inChina has obtained approval to market their unique dermal filler Algeness® VL agarose facial injection filler, a 2.5% agarose...
2025-01-29 14:00
3567
Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital Chooses a United Imaging Next Generation PET/CT to Revolutionize the Study of Systems Physiology
HOUSTON, Jan. 28, 2025 /PRNewswire/ -- As pioneers in biomedical imaging and neuroscience, the researchers at the Athinoula A. Martinos Center for Biomedical Imaging atMassachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, have long appreciated the ...
2025-01-28 22:00
3565
CStone Partners with SteinCares to Market Sugemalimab in Latin America
* CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. * This marks CStone's third major global commercialization partnership for sugemalimab, with additional deals...
2025-01-27 12:30
3029
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the N...
2025-01-27 09:53
2876
Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
SYDNEY, Jan. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U...
2025-01-24 22:02
4738
Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors
SINGAPORE and PHILADELPHIA, Jan. 24, 2025 /PRNewswire/ -- Nuevocor
2025-01-24 22:00
4994
NUS researchers pioneer DNA-tagged gold nanoparticles for targeted cancer treatment
Using DNA barcoding, the novel technique tracks and optimises gold nanoparticles for precise drug delivery to tumours, advancing cancer therapies that are safer and more effective SINGAPORE, Jan. 24, 2025 /PRNewswire/ -- A team of researchers from the National University of Singapore (NUS) has d...
2025-01-24 15:55
3258
Kexing Biopharm Participates in the 17th Biotech Showcase, with Multiple Innovation Pipelines Gaining Attention
SHENZHEN, China, Jan. 24, 2025 /PRNewswire/ -- From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase Conference inSan Francisco and the Global Biopharma Symposium hosted by Jones Day & MSQ Ventures. The Jones...
2025-01-24 14:59
3206
Datasea Announces Continued Expansion with Agreements to Place its Acoustic High-Tech Products in an Additional 200 Beauty Stores in Northern China
With the New Agreements, Products to be Placed in a Total of 463 New Stores with Total Projected Sales of 260,000 Units and Revenue of $19 Million Expected by Year End 2025 BEIJING, Jan. 23, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS), a Nevada -based digital technology company specializing...
2025-01-23 22:30
4449
Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology
Newly published study in collaboration with Japan's NCCHE reveals how AI-powered HER2 and tumor microenvironment analysis improves patient stratification and clinical outcome predictions SEOUL, South Korea, Jan. 23, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered sol...
2025-01-23 22:00
4180
Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")is excited to announce that the prestigious medical journal Nature Medicine published the results of the company's independently developed PD-1/CTLA-4 bispecific antibody cadonilimab in combination with oxali...
2025-01-23 08:31
2470
GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy
SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- GI Innovation
2025-01-22 21:00
3294
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 277 media titles]
2025-12-26 12:55Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 263 media titles]
2025-12-22 15:56
"Nihao China" App Launches as an All-in-One Solution for International Visitors
[Picked up by 253 media titles]
2025-12-24 17:54Sobot Shines in G2 Winter 2026: A New Benchmark in AI Customer Service
[Picked up by 252 media titles]
2025-12-24 10:00